You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR inhibitor

Showing 1 - 25 of 7,524
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cholangiocarcinoma Metastatic Trial in China (TT-00420 (tinengotinib))

Not yet recruiting
  • Cholangiocarcinoma Metastatic
  • TT-00420 (tinengotinib)
  • Guangzhou, Guangdong, China
  • +6 more
Sep 26, 2023

Solid Tumor Trial in Beijing (HMPL-453, gemcitabine and cisplatin, toripalimab)

Recruiting
  • Solid Tumor
  • Beijing, China
    Chinese PLA General Hospital
Mar 4, 2022

Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

Not yet recruiting
  • Cholangiocarcinoma
  • Tinengotinib 8 mg
  • +2 more
  • Santa Monica, California
  • +13 more
Jul 7, 2023

Advanced Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma Trial in

Recruiting
  • Advanced Hepatocellular Carcinoma
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 30, 2023

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, NSCLC, KRAS Gene Mutation Trial in Santa Monica,

Recruiting
  • Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations
  • +2 more
  • Futibatinib and Binimetinib
  • Santa Monica, California
  • +2 more
Jun 2, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor

Completed
Has Results
  • Advanced Lymphoma
  • +5 more
  • FGFR Inhibitor AZD4547
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 8, 2021

Urothelial Carcinoma Trial in Shanghai (AZD4547, Tislelizumab)

Recruiting
  • Urothelial Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 8, 2023

Cancer Trial in St. Gallen (Rogaratinib (BAY1163877), Combination drug)

Completed
  • Cancer
  • Rogaratinib (BAY1163877)
  • Combination drug
  • St. Gallen, Sankt Gallen, Switzerland
    Kantonsspital St. Gallen
Mar 20, 2022

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Achondroplasia Trial in Australia, Spain, United Kingdom (Infigratinib)

Recruiting
  • Achondroplasia
  • Parkville, Victoria, Australia
  • +3 more
Apr 5, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)

Active, not recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

Solid Tumor, Adult Trial in Shanghai (Highly selective FGFR1-3 inhibitor)

Recruiting
  • Solid Tumor, Adult
  • Highly selective FGFR1-3 inhibitor
  • Shanghai, China
    Shanghai East Hospital
Aug 26, 2021

Advanced Solid Tumors Trial in Beijing (EVER4010001)

Recruiting
  • Advanced Solid Tumors
  • Beijing, Beijing, China
    Department of Gastrointestinal Oncology, the Fifth Medical Cente
Jan 5, 2021

Solid Tumor Trial in Worldwide (Debio 1347)

Terminated
  • Solid Tumor
  • Debio 1347
  • Scottsdale, Arizona
  • +104 more
Mar 30, 2022

Achondroplasia Trial in Worldwide (Infigratinib 0.016 mg/kg, Infigratinib 0.032 mg/kg, Infigratinib 0.064 mg/kg)

Recruiting
  • Achondroplasia
  • Infigratinib 0.016 mg/kg
  • +3 more
  • Oakland, California
  • +17 more
Apr 5, 2022

Biliary Tract Tumors, Gastric Cancer, Esophageal Squamous Cell Carcinoma Trial in Beijing (FGFR Inhibitor, IDH1 Inhibitor, HER2

Unknown status
  • Biliary Tract Neoplasms
  • +8 more
  • FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
  • Other Therapy
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Oct 8, 2020

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter Trial in Spain, United States (PRN1371)

Terminated
  • Solid Tumors
  • Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
  • San Francisco, California
  • +11 more
Dec 23, 2020

Tumors Trial in Worldwide (Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib

Completed
Has Results
  • Neoplasms
  • Rogaratinib (BAY1163877) oral solution
  • +2 more
  • Chicago, Illinois
  • +28 more
Apr 12, 2021

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022